[go: up one dir, main page]

UY31350A1 - (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos - Google Patents

(carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos

Info

Publication number
UY31350A1
UY31350A1 UY31350A UY31350A UY31350A1 UY 31350 A1 UY31350 A1 UY 31350A1 UY 31350 A UY31350 A UY 31350A UY 31350 A UY31350 A UY 31350A UY 31350 A1 UY31350 A1 UY 31350A1
Authority
UY
Uruguay
Prior art keywords
procedure
preparation
phenyloxamids
carboxilalquilenfenil
medicinal product
Prior art date
Application number
UY31350A
Other languages
English (en)
Inventor
Dietrich Viktoria
Dr Johanna Kuhlmann
Dr Stefan Bartoschek
Dr Guido Haschke
Dr Siegfried Stengelin
Dr Thomas Klabunde
Dr Elisabeth Defossa
Herling Andreas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31350A1 publication Critical patent/UY31350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bisfeniloxamidas, procedimiento para su preparación y su utilización como productos farmacéuticos. La invencion se refiere a bisfeniloxamidas y a sus sales fisiológicamente toleradas. La invencion de refiere a compuestos de la fórmula I en la que R1,R2,R3,R4,R5,R6,R7,R8, m y X tienen los significados indicados, y una de sus sales fisiológicamente toleradas. Los compuestos son adecuados, por ejemplo, para el tratamiento de la diabetes.
UY31350A 2007-09-21 2008-09-19 (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos UY31350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291132 2007-09-21

Publications (1)

Publication Number Publication Date
UY31350A1 true UY31350A1 (es) 2009-04-30

Family

ID=39111451

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31350A UY31350A1 (es) 2007-09-21 2008-09-19 (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos

Country Status (20)

Country Link
US (2) US8518875B2 (es)
EP (1) EP2203416B1 (es)
JP (1) JP5427784B2 (es)
KR (1) KR20100061692A (es)
CN (1) CN101796017A (es)
AR (1) AR068479A1 (es)
AU (1) AU2008303976B9 (es)
CA (1) CA2700028A1 (es)
CL (1) CL2008002742A1 (es)
CO (1) CO6260062A2 (es)
IL (1) IL204555A0 (es)
MA (1) MA31710B1 (es)
MX (1) MX2010002461A (es)
MY (1) MY149648A (es)
NZ (1) NZ584049A (es)
RU (1) RU2488578C2 (es)
TW (1) TWI439265B (es)
UY (1) UY31350A1 (es)
WO (1) WO2009039943A1 (es)
ZA (1) ZA201001015B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010336225A1 (en) 2009-12-25 2012-08-16 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
BR112013004882A2 (pt) 2010-08-31 2016-05-03 Snu R&Db Foundation utilização de reprogramação fetal de agonista ppar delta
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
AU2012248629A1 (en) 2011-04-27 2013-11-28 Mochida Pharmaceutical Co., Ltd. Novel 3-hydroxyisothiazole 1-oxide derivative
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013102626A1 (en) * 2012-01-04 2013-07-11 Sanofi 3-[4-(phenylaminooxalylamino)phenyl]hex-4-ynoic acids, process for preparation thereof and use thereof as a medicament
IN2015DN03795A (es) 2012-10-24 2015-10-02 Inserm Inst Nat De La Santé Et De La Rech Médicale
WO2015046317A1 (ja) * 2013-09-30 2015-04-02 国立大学法人岡山大学 新規アセチレンアミド誘導体
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2016151018A1 (en) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of diabetes
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7242702B2 (ja) 2018-04-19 2023-03-20 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
EP3870566A1 (en) 2018-10-24 2021-09-01 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN114945560B (zh) 2019-10-07 2024-08-13 卡尔优普公司 Gpr119激动剂
CN114728917B (zh) * 2019-12-04 2023-12-08 深圳信立泰药业股份有限公司 草酰胺类衍生物、其制备方法及其在医药上的应用
KR20230012597A (ko) 2020-05-19 2023-01-26 칼리오페, 인크. Ampk 활성화제
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1618197B1 (de) * 1966-02-07 1971-12-09 Ciba Geigy Verwendung von asymmetrischen Oxalsäure-diarylamiden als Ultraviolettschutzmittel für organische Materialien
FR2727114B1 (fr) * 1994-11-17 1996-12-27 Oreal Nouveaux filtres solaires, compositions cosmetiques photoprotectrices les contenant et utilisations
CA2819705C (en) * 1998-02-02 2014-07-08 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US6890568B2 (en) * 1999-05-24 2005-05-10 Grant Pierce Method for management of blood glucose levels
US6867299B2 (en) * 2000-02-24 2005-03-15 Hoffmann-La Roche Inc. Oxamide IMPDH inhibitors
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
MXPA03010724A (es) * 2001-05-25 2004-03-02 Boehringer Ingelheim Pharma Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
ITRM20020016A1 (it) * 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
JP4224979B2 (ja) * 2002-04-09 2009-02-18 大正製薬株式会社 インターロイキン１２抑制剤
PL215132B1 (pl) * 2002-06-27 2013-10-31 Novo Nordisk As Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca
US20050124667A1 (en) * 2003-10-30 2005-06-09 Eric Sartori Oxamide inhibitors of plasminogen activator inhibitor-1

Also Published As

Publication number Publication date
WO2009039943A1 (de) 2009-04-02
EP2203416A1 (de) 2010-07-07
TW200927088A (en) 2009-07-01
RU2488578C2 (ru) 2013-07-27
TWI439265B (zh) 2014-06-01
CL2008002742A1 (es) 2009-01-16
JP5427784B2 (ja) 2014-02-26
NZ584049A (en) 2011-05-27
IL204555A0 (en) 2010-11-30
MA31710B1 (fr) 2010-09-01
AU2008303976B2 (en) 2013-04-18
AU2008303976B9 (en) 2013-09-12
RU2010115748A (ru) 2011-10-27
AR068479A1 (es) 2009-11-18
US20100261645A1 (en) 2010-10-14
CA2700028A1 (en) 2009-04-02
MX2010002461A (es) 2010-03-26
CN101796017A (zh) 2010-08-04
JP2010539199A (ja) 2010-12-16
ZA201001015B (en) 2010-10-27
EP2203416B1 (de) 2016-10-26
CO6260062A2 (es) 2011-03-22
KR20100061692A (ko) 2010-06-08
MY149648A (en) 2013-09-30
US20130231388A1 (en) 2013-09-05
AU2008303976A1 (en) 2009-04-02
US8518875B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
UY30338A1 (es) Acidos carboxilicos sustituidos con fenilaminobenzoxazol, procedimientos para su preparacion y su uso como productos farmacéuticos.
UY30337A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilo, procedimientos para su preparacion y su uso como productos farmacéuticos.
DOP2011000218A (es) Derivados de sulfonamida
UY30339A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos
UY33483A (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento.
CR20150326A (es) Inhibidores de autotaxina
CO6430456A2 (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
UY31918A (es) Compuestos de pirazol inhibidores de fgfr, composiciones farmaceuticas que los comprenden, procesos para su preparacion y su uso como medicamento
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY31631A1 (es) Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
UY28955A1 (es) Nuevos derivados fluoroglicosídicos de pirazoles, medicamentos que contienen estos compuestos, y el empleo de los mismos
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
UY31141A1 (es) Compuestos de piperidina y sus usos
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
CR20110210A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY35091A (es) Formulaciones de liberacion modificada para oprozomib

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140729